Cardiology Department 2

51. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
52. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC
53. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
54. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
55. Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050
56. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019
57. Arterial Hypertension and Associated Risk Factors in Kazakhstan: An Analysis of Blood Pressure Screening Results from May Measurement Month 2021–2023
58. Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology
59. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)
60. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry
61. Patient-Reported Outcomes After First Pulmonary Vein Isolation for ParoxYsmal Atrial Fibrillation: Cryoballoon vs. Radiofrequency (SPY-AF)
62. Patient-Reported Outcomes After First Pulmonary Vein Isolation for ParoxYsmal Atrial Fibrillation: Cryoballoon vs. Radiofrequency (SPY-AF)
63. Patient-Reported Outcomes After First Pulmonary Vein Isolation for ParoxYsmal Atrial Fibrillation: Cryoballoon vs. Radiofrequency (SPY-AF)
64. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology
65. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology
66. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
67. Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019
68. Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: A call to action from the cardio-kidney community
69. Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: A call to action from the cardio-kidney community
70. Optimization of Renin-Angiotensin-Aldosterone Inhibitor Therapies for Evidence-Based Indications: a Call to Action From the Cardio-Kidney Community
71. Optimization of Renin-Angiotensin-Aldosterone Inhibitor Therapies for Evidence-Based Indications: a Call to Action From the Cardio-Kidney Community
72. Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: a call to action from the cardio-kidney community
73. Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: a call to action from the cardio-kidney community
74. 2025 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
75. 2025 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
76. 2025 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
77. 2025 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
78. Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology
79. Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology
80. Prognosis of PCI in AMI setting in the elderly population: Outcomes from the multicenter prospective e-ULTIMASTER registry
81. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC
82. Mapping routine measles vaccination in low- and middle-income countries
83. 2025 ESC Guidelines for the management of myocarditis and pericarditis
84. Prevention and rehabilitation after heart transplantation: A clinical consensus statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a section of ESOT
85. Prevention and rehabilitation after heart transplantation: A clinical consensus statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a section of ESOT
86. Prevention and Rehabilitation After Heart Transplantation: A Clinical Consensus Statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a Section of ESOT
87. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
88. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
89. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
90. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
91. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
92. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
93. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
94. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
95. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
96. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
97. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
98. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
99. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
100. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
1 2 3